Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | JUN | P05412 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617910 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL617909 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL3017778 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL621130 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL621129 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL7523532 | 0.86 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL7523536 | 0.86 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL7514670 | 0.86 | CHRNB2 (0.71) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL9519915 | 0.86 | CHRNB2 (0.71) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL7514662 | 0.86 | CHRNB2 (0.71) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288420-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7790757-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-0900200-B9 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1997806-A1 | Pahrmaceutical compositions for prevention and treatment of central nervous system disorders | Targacept, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-0900200-B1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2008-12-03 | — | — | EP | disclosed |
| US-6492399-B1 | SUCH AS N-METHYL-4-(3-(5-NITRO-6-AMINOPYRIDIN)YL)-3-BUTEN-1-AMINE; NICOTINIC CHOLINERGIC RECEPTOR AGONISTS | TARGACEPT, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-0900200-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885MEN1 2465/4885 |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885MEN1 2465/4885 |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | PMP22, AANAT, CHAT | CHRNB2 17/4885CHRNA4 8/4885MEN1 1886/4885 |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885MEN1 2465/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885MEN1 1543/4885 |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885MEN1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.